Relief of periorbital pain after acute angle closure glaucoma attack by botulinum toxin type A

Journal of Glaucoma

Volumn 19, Issue 8, 2010, Pages 546-550

  Chien, Ke Hung ^a   Lu, Da Wen ^a   Chen, Yi Hao ^a   Cheng, Jen Hao ^a   Chen, Jiann Torng ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Angle closure glaucoma; botox; botulinum toxin type A; periorbital pain

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ACUTE DISEASE; ADULT; AGED; ANALGESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INJECTION SITE REACTION; INJECTION SITE STINGING; INTRACTABLE PERIORBITAL PAIN; INTRAOCULAR PRESSURE; IRIDOTOMY; LOCAL TENDERNESS; MALE; MUSCLE WEAKNESS; ORBIT DISEASE; PRIORITY JOURNAL; PTOSIS; QUALITY OF LIFE INDEX; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS HEMORRHAGE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ACUTE DISEASE; AGED; ANTIHYPERTENSIVE AGENTS; BOTULINUM TOXINS, TYPE A; EYE PAIN; FEMALE; GLAUCOMA, ANGLE-CLOSURE; GONIOSCOPY; HUMANS; INTRAOCULAR PRESSURE; IRIDECTOMY; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; ORBITAL DISEASES; PAIN MEASUREMENT; PAIN, INTRACTABLE; PALLIATIVE CARE; PROSPECTIVE STUDIES; TONOMETRY, OCULAR;

EID: 77958591667     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3181ca76a9     Document Type: Article

References (26)

1. Foster PJ, Johnson GJ. Glaucoma in China: how big is the problem? Br J Ophthalmol. 2001;85:1277-1282.
2. Seah SK, Foster PJ, Chew PT, et al. Incidence of acute primary angle-closure glaucoma in Singapore. An island-wide survey. Arch Ophthalmol. 1997;115:1436-1440.
3. Vles GF, de Louw AJ, Speth LA, et al. Visual Analogue Scale to score the effects of Botulinum Toxin A treatment in children with cerebral palsy in daily clinical practice. Eur J Paediatr Neurol. 2008;12:231-238.
4. Bushnell DM, Martin ML, Ricci JF, et al. Performance of the EQ-5D in patients with irritable bowel syndrome. Value Health. 2006;9:90-97.
5. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095-1108.
6. Piovesan EJ, Teive HG, Kowacs PA, et al. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology. 2005;65:1306-1308.
7. Stone CA, O'Leary N. Systematic review of the effectiveness of botulinum toxin or radiotherapy for sialorrhea in patients with amyotrophic lateral sclerosis. J Pain Symptom Manage. 2009; 37:246-258.
8. Wong TY, Loon SC, Saw SM. The epidemiology of age related eye diseases in Asia. Br J Ophthalmol. 2006;90:506-511.
9. Lavanya R, Wong TY, Friedman DS, et al. Determinants of angle closure in older Singaporeans. Arch Ophthalmol. 2008; 126:686-691.
10. Wong TY, Foster PJ, Seah SK, et al. Rates of hospital admissions for primary angle closure glaucoma among Chinese, Malays, and Indians in Singapore. Br J Ophthalmol. 2000;84:990-992.
11. Goldberg I, Clement CI, Chiang TH, et al. Assessing quality of life in patients with glaucoma using the Glaucoma Quality of Life-15 (GQL-15) questionnaire. J Glaucoma. 2009;18:6-12.
12. Skalicky S, Goldberg I. Depression and quality of life in patients with glaucoma: a cross-sectional analysis using the Geriatric Depression Scale-15, assessment of function related to vision, and the Glaucoma Quality of Life-15. J Glaucoma. 2008;17:546-551.
13. Azar M, Yahyavi ST, Bitaraf MA, et al. Gamma knife radio-surgery in patients with trigeminal neuralgia: quality of life, outcomes, and complications. Clin Neurol Neurosurg. 2009; 111:174-178.
14. Zhang X, Li A, Ge J, et al. Acute increase of intraocular pressure releases ATP into the anterior chamber. Exp Eye Res. 2007;85:637-643.
15. Ranoux D, Attal N, Morain F, et al. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64:274-283.
16. Malcangio M, Tomlinson DR. A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain. 1998;76:151-157.
17. Skogseid IM, Malt UF, Roislien J, et al. Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. Eur J Neurol. 2007;14:1129-1137.
18. Mehta RP, Hadlock TA. Botulinum toxin and quality of life in patients with facial paralysis. Arch Facial Plast Surg. 2008;10: 84-87.
19. Ruiz Huete C, Bermejo PE. [Botulinum toxin type A in the treatment of neuropathic pain in a case of postherpetic neuralgia]. Neurologia. 2008;23:259-262.
20. Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain. A randomized double-blind crossover trial. Neurology. 2009;72:1473-1478.
21. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003;43(suppl 1): S9-S15.
22. Majlesi G. GaAs laser treatment of bilateral eyelid ptosis due to complication of botulinum toxin type A injection. Photomed Laser Surg. 2008;26:507-509.
23. Korn BS, Seo SW, Levi L, et al. Optic neuropathy associated with botulinum A toxin in thyroid-related orbitopathy. Ophthal Plast Reconstr Surg. 2007;23:109-114.
24. Northington ME, Huang CC. Dry eyes and superficial punctate keratitis: a complication of treatment of glabelar dynamic rhytides with botulinum exotoxin a. Dermatol Surg. 2004;30:1515-1517.
25. Paloma V, Samper A. A complication with the aesthetic use of Botox: herniation of the orbital fat. Plast Reconstr Surg. 2001; 107:1315.
26. Latimer PR, Hodgkins PR, Vakalis AN, et al. Necrotising fasciitis as a complication of botulinum toxin injection. Eye. 1998;12:51-53.